The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Vaccine manufacturing is lumpy, supply not as good as hoped, UK says

Mon, 18th Jan 2021 08:16

* UK says AstraZeneca slower than hoped

* UK says Pfizer changes may lead to delays

* UK is vaccinating 140 people per minute on average
(Recasts headline and lead with manufacturing issues)

By Guy Faulconbridge and Kate Holton

LONDON, Jan 18 (Reuters) - Britain's vaccine rollout is
limited by a "lumpy" manufacturing process with production
changes by Pfizer and a delay by AstraZeneca
that could lead to brief supply disruption, Vaccine Deployment
Minister Nadhim Zahawi said on Monday.

The United Kingdom, which has the world's fifth worst
official COVID-19 death toll, is racing to be among the first
major countries to vaccinate its population - seen as the best
way to exit the pandemic and get the economy going again.

The United Kingdom has vaccinated 3,857,266 people with a
first dose and 449,736 with a second dose. On vaccines
administered per 100 people, the United Kingdom is fourth in the
world after Israel, the United Arab Emirates and Bahrain.

Zahawi told LBC radio that the United Kingdom was hoping for
2 million vaccines a week from AstraZeneca but that
those numbers will not be reached until mid February. Still, he
said the UK was on course to hit its rollout targets.

"It's been a bit lumpy," Zahawi said of vaccine manufacture.

Pfizer will temporarily reduce its deliveries to Europe of
its vaccine against COVID-19 while it upgrades its production
capacity.

"There's bound to be delays. Any new manufacturing process
has challenges at the outset, it is lumpy, it begins to
stabilise and get better and better week in, week out," Zahawi
told the BBC.

"The Pfizer BioNTech vaccine is a messenger RNA chemical,
difficult chemical to manufacture, very very challenging but
they're doing really well, they want to do more which is why
they're reconfiguring to add volume to the whole world," Zahawi
said.

"That could delay supply but I'm confident we can meet our
target."

VACCINE HOPES

Mass COVID-19 vaccines are seen as the best way to exit the
pandemic which has killed more than 2 million people, wiped out
trillions of dollars in economic output and upended normal life
for people across the world.

The United Kingdom is vaccinating 140 people per minute
against COVID-19 on average.

"It is going well, we're vaccinating on average 140 people,
that's first jab, literally a minute. That's the average so some
areas are doing better," Zahawi told Sky.

Britain is currently rolling out the vaccine to the most
vulnerable first, starting with those who are in care homes or
over 80 years of age. In areas where a majority of over 80s have
been offered a vaccine, letters are going out to the over 70s
and those who are clinically extremely vulnerable.

Zahawi said a 24-hour vaccine offering would begin to be
piloted in London by the end of the month.

Essential workers such as teachers, the police and shop
assistants could move to the top of the list for a vaccine once
all those over 50 have been offered a shot, Zahawi said.

"Teachers, police officers, shop workers, those who through
no fault of their own other than the work that they do may come
into contact with the virus in much greater volume, should be
top of the list," Zahawi told Times Radio.
(Reporting by Guy Faulconbridge and Kate Holton; editing by
Sarah Young, Paul Sandle and Philippa Fletcher)

More News
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.